Eclipse Bioinnovations, Inc.
San Diego, CA
- UEI
- NKBUXMSL35L8
- CAGE
- 7XLH4
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 5770 Oberlin Dr, San Diego, CA 92121, USA
- Website
- eclipsebio.com
- Founded
- 2017
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Emoa: a multi-omic service for mechanism of action determination in drug screening - summary the pathway to a successful… | National Institute of General Medical Sciences | $4,007,848 | |
| Development of chimeric read amplification into a robust method for profiling targets of specific micrornas and global… | National Human Genome Research Institute | $5,136,148 | |
| Unambiguous transcriptome-wide identification of microrna:mrna interactions through enhanced chimeric read amplification | National Human Genome Research Institute | $349,750 | |
| A robust kit, standards, and software for identifying RNA binding protein targets | National Human Genome Research Institute | $1,583,111 |
About Eclipse Bioinnovations, Inc.
Eclipse Bioinnovations, Inc. is a for-profit organization registered with the U.S. federal government to receive contract and grant awards. The company specializes in developing innovative genomic and bioinformatics technologies for biomedical research and drug discovery. Eclipse Bioinnovations has received multiple federal grant awards from the National Institutes of Health (NIH), particularly from the National Institute of General Medical Sciences (NIGMS) and the National Human Genome Research Institute (NHGRI). These awards support the company's efforts to create advanced platforms and methodologies for analyzing RNA interactions, gene expression, and drug mechanisms of action.
The company's grant-funded projects focus on developing cutting-edge technologies for biomedical research. One such project is the EMOA (Enhanced Multi-Omic Analysis) platform, funded by NIGMS, which aims to provide a multi-omic service for rapid mechanism of action determination in drug screening. This platform combines transcriptomics and translatomics to quickly identify candidate drug compounds and elucidate their precise mechanisms of action, potentially shortening the drug discovery research cycle for biotech and pharmaceutical companies. Another significant project, funded by NHGRI, involves the development of Chimeric-eCLIP technology. This method enables unambiguous identification of microRNA targets in a transcriptome-wide manner, allowing for more precise understanding of microRNA regulation in cellular processes and diseases. The Chimeric-eCLIP project aims to create a robust and versatile kit for widespread use in academic and biotechnology industries, including the development of user-friendly analysis tools and expanded beta testing for commercialization.
Quick answers
What is Eclipse Bioinnovations, Inc.'s UEI?
Eclipse Bioinnovations, Inc.'s Unique Entity ID (UEI) in SAM.gov is NKBUXMSL35L8.
What is Eclipse Bioinnovations, Inc.'s CAGE code?
Eclipse Bioinnovations, Inc.'s CAGE code is 7XLH4.
Where is Eclipse Bioinnovations, Inc. located?
Eclipse Bioinnovations, Inc.'s physical address in SAM.gov is 5770 Oberlin Dr, San Diego, CA 92121, USA.
Is Eclipse Bioinnovations, Inc. registered in SAM.gov?
Yes. Eclipse Bioinnovations, Inc.'s SAM.gov registration is active through December 8, 2026.
What is Eclipse Bioinnovations, Inc.'s most recent federal award?
Eclipse Bioinnovations, Inc.'s most recent federal grant award is Emoa: a multi-omic service for mechanism of action determination in drug screening - summary the pathway to a successful… (R44GM154583), from National Institute of General Medical Sciences, on July 1, 2024.
On GovTribe
See Eclipse Bioinnovations, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors